2022-502634-52-00进行中（未招募）3 期
A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 (in a 3 week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4 week cycle) in combination with Darolutamide + ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC)
Friedrich-Schiller-Universitaet Jena46 个研究点 分布在 2 个国家目标入组 280 人开始时间: 2023年5月12日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 280
- 试验地点
- 46
- 主要终点
- “Occurrence of a high grade (3 to 5) adverse event” (yes/no), which will be analyzed 26 weeks after last patient first docetaxel dose (LPFD), will be summarized as adverse event (AE) rate (AER). A secondary safety endpoint is “Occurence of neutropenia grade 3/4 AE or death regardless of reason”, which will be summarized as neutropenia AE rate (NAER)
研究概览
简要总结
The main objective is to compare grade 3-5 adverse event rate (AER) in patients with mHSPC treated with 6 cycles of either Docetaxel 75 mg/m2 every 3 weeks in a 3 week cycle or Docetaxel 50 mg/m2 every 2 weeks in a 4 week cycle in combination with Darolutamide + ADT, A secondary safety endpoint is “Occurence of neutropenia grade 3/4 AE or death regardless of reason”, which will be summarized as neutropenia AE rate (NAER)
研究设计
- 分配方式
- Randomized
- 主要目的
- Experimental Arm
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Screening values of serum alanine aminotransferase and/or aspartate transaminase ≤1.5x upper limit of normal (ULN), total bilirubin ≤ULN, creatinine ≤2.0x ULN
- •Sexually active male subjects must agree to use condoms as an effective barrier method and refrain from sperm donation, and/or their female partners of reproductive potential to use a method of effective birth control, during the treatment with docetaxel and darolutamide, 6 months after end of the treatment with docetaxel and for 3 months after the end of the treatment with darolutamide
- •Males ≥18 years of age
- •Histologically or cytologically confirmed adenocarcinoma of prostate
- •Investigator assessed metastatic disease documented either by a positive bone scan, or for soft tissue or visceral metastases, either by contrast-enhanced abdominal/pelvic/chest computed tomography (CT) or magnetic resonance imaging (MRI) scan assessed. Metastatic disease is defined as either malignant lesions in bone scan or soft tissue/visceral lesions according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.
- •Lymph nodes are measurable if the short axis diameter is ≥15 mm, soft tissue/visceral lesions are measurable if the long axis diameter is ≥10 mm.
- •Subjects with lymph node metastases only (either below the aortic bifurcation (N1) or above the aortic bifurcation (M1a)) will not be eligible for the study
- •Subjects must be candidates for ADT, docetaxel and darolutamide therapy per Investigator's judgment
- •Started ADT (LHRH agonist/antagonist or orchiectomy) with or without first generation anti-androgen, but no longer than 12 weeks before randomization. For subjects receiving LHRH agonists, treatment in combination with a first generation anti-androgen for at least 4 weeks, prior to randomization is recommended. First generation anti-androgen has to be stopped prior to randomization
- •An Eastern Cooperative Oncology Group performance status of 0 or 1
- •Blood counts at Screening: hemoglobin ≥9.0 g/dL, absolute neutrophil count ≥1.5x109/L, platelet count ≥100x109/L (subject must not have received any growth factor within 4 weeks or a blood transfusion within 7 days of the hematology laboratory sample obtained at Screening)
排除标准
- •Prior treatment with: LHRH agonist/antagonists started more than 12 weeks before randomization,o Second-generation androgen receptor (AR) inhibitors such as enzalutamide, apalutamide, darolutamide, other investigational AR inhibitors,o Cytochrome P 17 enzyme inhibitor such as abiraterone acetate or oral ketoconazole as antineoplastic treatment for prostate cancer,o Chemotherapy, immunotherapy, radium or other therapeutic radiopharmaceuticals for prostate cancer (e.g. Lutetium177-PSMA) prior to randomization
- •Previous (within 28 days before the start of study drug or 5 half-lives of the investigational treatment of the previous study, whichever is longer) or concomitant participation in another clinical study with investigational medicinal product(s)
- •Any other serious or unstable illness, or medical, social, or psychological condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results
- •Inability to swallow oral medications
- •Previous assignment to treatment in this study
- •Treatment with radiotherapy (external beam radiation therapy, brachytherapy) within 2 weeks before randomization
- •Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
- •Contraindication to both CT and MRI contrast agent
- •Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris,coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV)
- •Uncontrolled hypertension as indicated by a resting systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg despite medical management
- •Had a prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any other cancer for which treatment has been completed ≥5 years before randomization and from which the subject has been disease-free
- •A gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study drug
- •An active viral hepatitis, known human immunodeficiency virus infection with detectable viral load, or chronic liver disease with a need for treatment
结局指标
主要结局
“Occurrence of a high grade (3 to 5) adverse event” (yes/no), which will be analyzed 26 weeks after last patient first docetaxel dose (LPFD), will be summarized as adverse event (AE) rate (AER). A secondary safety endpoint is “Occurence of neutropenia grade 3/4 AE or death regardless of reason”, which will be summarized as neutropenia AE rate (NAER)
“Occurrence of a high grade (3 to 5) adverse event” (yes/no), which will be analyzed 26 weeks after last patient first docetaxel dose (LPFD), will be summarized as adverse event (AE) rate (AER). A secondary safety endpoint is “Occurence of neutropenia grade 3/4 AE or death regardless of reason”, which will be summarized as neutropenia AE rate (NAER)
次要结局
- PSA-response (PSA ≤0.2, >0.2-4.0 und >4.0 ng/ml) determined at week 26 after LPFD
- Time to castration-resistant prostate cancer
- Overall survival
- Time to initiation of subsequent antineoplastic therapy
- Time to first symptomatic skeletal event (SSE)
- Time to pain progression
- Time to worsening of physical symptoms of disease based on functional assessment of cancer therapy / National Comprehensive Cancer Network prostate cancer symptom index 17 item questionnaire (NCCN-FACT FPSI-17)
- Treatment emergent adverse events according to NCI-CTCAE version 5.0
- Long-term overall safety and tolerability
- Quality of life
- Prostate-specific antigen (PSA) assessments
- Docetaxel-exposure-response analysis
研究者
Sponsor representative and medical expert
Scientific
Friedrich-Schiller-Universitaet Jena
研究点 (46)
Loading locations...
相似试验
尚未招募
3 期
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye DiseaseNCT07262476Minghui Pharmaceutical (Hangzhou) Ltd258
已完成
4 期
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis2023-504869-23-00AbbVie Deutschland GmbH & Co. KG272
尚未招募
3 期
MHB018A Treatment in Patients With Chronic Thyroid Eye DiseaseNCT07257185Minghui Pharmaceutical (Hangzhou) Ltd150
招募中
1 期
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor PatientsNCT07260305Kangabio AUSTRALIA LTD PTY57
招募中
3 期
A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk MDS2022-500479-29-00Celgene Corp.166